(Q36648893)

15 August 2017

IPM chemotherapy in cytokine refractory renal cell cancer (English)

1 reference

15 August 2017

1 reference

J Shamash

1

1 reference

15 August 2017

J P Steele

2

1 reference

15 August 2017

P Wilson

3

1 reference

15 August 2017

M Nystrom

4

1 reference

15 August 2017

W Ansell

5

1 reference

15 August 2017

R T D Oliver

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

88

1 reference

15 August 2017

10

1 reference

15 August 2017

1516-1521

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600934

15 August 2017

0 references

cites work

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

The treatment of advanced renal cell cancer with high-dose oral thalidomide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.

28 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377110

28 June 2018

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600934

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

21 January 2018

1 reference

12 December 2020

Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600934

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

12771915

1 reference